Just as a follow up, GNVC continues to have positive, but not yet financially positive releases. Some of the releases have raised the prices temporarily, but it seems that increases in stock price won't be sustained until their is either money attached, or the company at least addresses how the company should grow financially as its products advance in the clinic.
With the exception of FMD Vaccines, everything else GNVC has going for it is either in early stage clinical trial or in the case of what may be it's biggest drug, Novartis's hearing and balance drug, preclinical. Certainly if either Merial or Homeland Security is ready to sell or stockpile the GNVC based vaccine, income may start routinely rolling in, but for the remainder of the pipeline, sales are probably at least 3, and more likely 5 or more years away.
When I say 3 years, I'm speaking of the hearing drug being in trials this year. Should Phase I actually produce substantial numbers of patients with hearing and/or balance disorder seeing substantial improvement, and no detrimental safety issues, I believe a Registrational Phase II could be established which could lead to an approval in 2 years or less with FDA cooperation. Clearly if the drug works for a substantial percentage of the patients it's tried on, the FDA ought to cooperate with it's approval as public demands will be great.
Gary |
